New diabetes drug shows promise in chinese patients
NCT ID NCT02916706
First seen Jan 09, 2026 · Last updated Apr 29, 2026 · Updated 13 times
Summary
This study tested a diabetes medication called teneligliptin in 254 Chinese adults with type 2 diabetes. Participants were randomly assigned to receive either teneligliptin or a placebo for 24 weeks. The main goal was to see if teneligliptin could lower blood sugar levels (HbA1c) more than placebo. The study also looked at changes in fasting blood sugar and overall safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational center
Beijing, China
Conditions
Explore the condition pages connected to this study.